These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 34449040

  • 1. Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
    Han W, Zhou F, Wang Z, Hua H, Qin W, Jia Z, Cai X, Chen M, Liu J, Chao H, Lu X.
    Int J Hematol; 2022 Jan; 115(1):21-32. PubMed ID: 34449040
    [Abstract] [Full Text] [Related]

  • 2. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
    Jian J, Qiao Y, Li Y, Guo Y, Ma H, Liu B.
    Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
    [Abstract] [Full Text] [Related]

  • 3. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
    Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP, Gangat N, Tefferi A.
    Blood Cancer J; 2016 Jan 15; 6(1):e385. PubMed ID: 26771811
    [Abstract] [Full Text] [Related]

  • 4. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
    Zhao W, Zhang C, Li Y, Li Y, Liu Y, Sun X, Liu M, Shao R.
    Hematology; 2022 Dec 15; 27(1):367-378. PubMed ID: 35306971
    [Abstract] [Full Text] [Related]

  • 5. Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
    Fei F, Jariwala A, Pullarkat S, Loo E, Liu Y, Tizro P, Ali H, Otoukesh S, Amanam I, Artz A, Ally F, Telatar M, Nakamura R, Marcucci G, Afkhami M.
    Int J Mol Sci; 2024 Sep 23; 25(18):. PubMed ID: 39337700
    [Abstract] [Full Text] [Related]

  • 6. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
    Ouyang Y, Qiao C, Chen Y, Zhang SJ.
    Oncotarget; 2017 Mar 28; 8(13):20834-20841. PubMed ID: 28209919
    [Abstract] [Full Text] [Related]

  • 7. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
    Schuler E, Frank F, Hildebrandt B, Betz B, Strupp C, Rudelius M, Aul C, Schroeder T, Gattermann N, Haas R, Germing U.
    Leuk Res; 2018 Feb 28; 65():1-4. PubMed ID: 29216536
    [Abstract] [Full Text] [Related]

  • 8. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
    Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, Arber DA.
    Mod Pathol; 2015 May 28; 28(5):706-14. PubMed ID: 25412851
    [Abstract] [Full Text] [Related]

  • 9. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
    Qu SQ, Pan LJ, Qin TJ, Xu ZF, Li B, Wang HJ, Sun Q, Jia YJ, Li CW, Cai WY, Gao QY, Jiao M, Xiao ZJ.
    Zhonghua Xue Ye Xue Za Zhi; 2023 May 14; 44(5):373-379. PubMed ID: 37550186
    [Abstract] [Full Text] [Related]

  • 10. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
    Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, Lee J, Zhao C, Stingo F, Zuo Z, Routbort MJ, Singh RR, Fox P, Ravandi F, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE.
    Oncotarget; 2016 Mar 22; 7(12):14251-8. PubMed ID: 26883102
    [Abstract] [Full Text] [Related]

  • 11. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
    Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B, Dicker F, Schnittger S, Dugas M, Kern W, Haferlach C, Haferlach T.
    J Clin Oncol; 2010 Aug 20; 28(24):3858-65. PubMed ID: 20644105
    [Abstract] [Full Text] [Related]

  • 12. Age-related mutations and chronic myelomonocytic leukemia.
    Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, Druker BJ, Gotlib J, O'Hare T, Deininger MW.
    Leukemia; 2016 Apr 20; 30(4):906-13. PubMed ID: 26648538
    [Abstract] [Full Text] [Related]

  • 13. Prognostic score including gene mutations in chronic myelomonocytic leukemia.
    Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Adès L, Fenaux P, Beyne-Rauzy O, Vey N, Braun T, Haferlach T, Dreyfus F, Cross NC, Preudhomme C, Bernard OA, Fontenay M, Vainchenker W, Schnittger S, Birnbaum D, Droin N, Solary E.
    J Clin Oncol; 2013 Jul 01; 31(19):2428-36. PubMed ID: 23690417
    [Abstract] [Full Text] [Related]

  • 14. Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.
    Chapman J, Geyer JT, Khanlari M, Moul A, Casas C, Connor ST, Fan YS, Watts JM, Swords RT, Vega F, Orazi A.
    Mod Pathol; 2018 Mar 01; 31(3):429-441. PubMed ID: 29192651
    [Abstract] [Full Text] [Related]

  • 15. Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.
    Kim HY, Lee KO, Park S, Jang JH, Jung CW, Kim SH, Kim HJ.
    Ann Lab Med; 2018 Nov 01; 38(6):495-502. PubMed ID: 30027691
    [Abstract] [Full Text] [Related]

  • 16. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
    Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, Gangat N, Binder M, Pardanani A, Fernandez-Zapico M, Robertson KD, Bosi A, Droin N, Vannucchi AM, Tefferi A, Hunter A, Padron E, Solary E, Patnaik MM.
    Leukemia; 2020 May 01; 34(5):1407-1421. PubMed ID: 31836856
    [Abstract] [Full Text] [Related]

  • 17. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.
    Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Knudson RA, Ketterling RP, Tefferi A, Solary E.
    Leukemia; 2014 Nov 01; 28(11):2206-12. PubMed ID: 24695057
    [Abstract] [Full Text] [Related]

  • 18. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
    You X, Liu F, Binder M, Vedder A, Lasho T, Wen Z, Gao X, Flietner E, Rajagopalan A, Zhou Y, Finke C, Mangaonkar A, Liao R, Kong G, Ranheim EA, Droin N, Hunter AM, Nikolaev S, Balasis M, Abdel-Wahab O, Levine RL, Will B, Nadiminti KVG, Yang D, Geissler K, Solary E, Xu W, Padron E, Patnaik MM, Zhang J.
    Blood; 2022 Feb 17; 139(7):1066-1079. PubMed ID: 34699595
    [Abstract] [Full Text] [Related]

  • 19. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R, Chiu MC, Huang YJ, Lin TH, Kuo MC, Shih LY.
    J Hematol Oncol; 2019 Oct 22; 12(1):104. PubMed ID: 31640815
    [Abstract] [Full Text] [Related]

  • 20. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
    Hwang SM, Kim SM, Nam Y, Kim J, Kim S, Ahn YO, Park Y, Yoon SS, Shin S, Kwon S, Lee DS.
    Leuk Res; 2019 Sep 22; 84():106190. PubMed ID: 31377458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.